Extravascular Binding of Coagulation Factor IX Gives Hemostasis a Boost
Ján Pilch, Lynn M. Knowles
Abstract
Ján Pilch, Lynn M. Knowles
Abstract
Hemophilia B is caused by a hereditary deficit of functional coagulation factor IX (FIX), which in its severe manifestation can be associated with spontaneous, debilitating bleeding episodes. Treatment of patients with severe hemophilia B has dramatically improved with the advent of extended half-life FIX concentrates. However, since these products are geared toward prolonged residence inside the vasculature, questions have been raised about the role of the extravascular compartment as a reservoir of FIX. Distribution of FIX into the extravascular compartment, which has been estimated to account for as much as 75% of total FIX, depends on specific residues in the γ-carboxyglutamic (Gla) domain of FIX.[ 1 ] Consequently, interactions of FIX with endothelial cells and the extravascular compartment were significantly reduced after exchanging residue 5 of the FXI Gla domain from lysine to alanine (rFIX K5A ) while the exchange to arginine (rFIX K5R ) conveyed increased interactions compared with recombinant wild-type FIX (rFIX WT ).[ 2 ] Using pharmacokinetic (PK) analysis in hemophilia B mice in vivo, Machado et al[ 3 ] demonstrate in this issue that the elimination of rFIX K5A is considerably slower than that of rFIX WT or rFIX K5R . The accelerated elimination of rFIX K5R and rFIX WT from the vascular compartment was attributed to a speedy redistribution into the extravascular compartment where rFIX K5R produced a prolonged positivity for FIX antigen. Increased deposition of rFIX K5R in the extracellular matrix correlated with reduced bleeding of hemophilia B mice for up to 7 days. In contrast, the rFIX K5A , which has essentially the same PK profile as rFIX K5R and rFIX WT in vitro, induced clotting in hemophilia B mice in vivo efficiently during early time points but efficacy began to fade after 24 hours when the activity of intravascular FIX was at or below the detection limit. Together, Machado et al demonstrate with their meticulous work that manipulating the interactions of FIX with endothelial cells and the connective tissue has important implications for the function of FIX and subsequent clotting. Open questions remain with regard to delineating the extravascular clotting activity of FIX and the underlying mechanism. Publication History Received: 28 February 2023 Accepted: 28 March 2023 Accepted Manuscript online: 03 April 2023 Article published online: 24 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Hemophilia B is caused by a hereditary deficit of functional coagulation factor IX (FIX), which in its severe manifestation can be associated with spontaneous, debilitating bleeding episodes. Treatment of patients with severe hemophilia B has dramatically improved with the advent of extended half-life FIX concentrates. However, since these products are geared toward prolonged residence inside the vasculature, questions have been raised about the role of the extravascular compartment as a reservoir of FIX. Distribution of FIX into the extravascular compartment, which has been estimated to account for as much as 75% of total FIX, depends on specific residues in the γ-carboxyglutamic (Gla) domain of FIX.[ 1 ] Consequently, interactions of FIX with endothelial cells and the extravascular compartment were significantly reduced after exchanging residue 5 of the FXI Gla domain from lysine to alanine (rFIX K5A ) while the exchange to arginine (rFIX K5R ) conveyed increased interactions compared with recombinant wild-type FIX (rFIX WT ).[ 2 ] Using pharmacokinetic (PK) analysis in hemophilia B mice in vivo, Machado et al[ 3 ] demonstrate in this issue that the elimination of rFIX K5A is considerably slower than that of rFIX WT or rFIX K5R . The accelerated elimination of rFIX K5R and rFIX WT from the vascular compartment was attributed to a speedy redistribution into the extravascular compartment where rFIX K5R produced a prolonged positivity for FIX antigen. Increased deposition of rFIX K5R in the extracellular matrix correlated with reduced bleeding of hemophilia B mice for up to 7 days. In contrast, the rFIX K5A , which has essentially the same PK profile as rFIX K5R and rFIX WT in vitro, induced clotting in hemophilia B mice in vivo efficiently during early time points but efficacy began to fade after 24 hours when the activity of intravascular FIX was at or below the detection limit. Together, Machado et al demonstrate with their meticulous work that manipulating the interactions of FIX with endothelial cells and the connective tissue has important implications for the function of FIX and subsequent clotting. Open questions remain with regard to delineating the extravascular clotting activity of FIX and the underlying mechanism. Publication History Received: 28 February 2023 Accepted: 28 March 2023 Accepted Manuscript online: 03 April 2023 Article published online: 24 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Key concepts: Hemostasis, Coagulation, Blood coagulation factors, Factor IX, Medicine, Thrombosis, Coagulopathy, Internal medicine